Encyclopedia of Autism Spectrum Disorders

Living Edition
| Editors: Fred R. Volkmar

Substance Use Problems/Disorders in Individuals with ASD

  • Roald A. ØienEmail author
  • Anders Nordahl-Hansen
  • Marek ChawarskiEmail author
Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-6435-8_102122-1

Introduction

Autism spectrum disorder (ASD) is a heterogeneous condition defined by social deficits, restrictive interests, and repetitive behaviors. Individuals with ASD demonstrate highly variable levels of intellectual abilities, verbal skills, and adaptive functioning (American Psychiatric Association 2013). Psychiatric and medical comorbidities are frequently co-occurring in ASD, including anxiety, depression, attention deficit hyperactivity disorder (ADHD), obsessive compulsive disorder (OCD), seizure disorder, sleep disorder, and a broad range of various somatic disorders (Bauman 2010; Joshi et al. 2010; Mattila et al. 2010; Muskens et al. 2017; Simonoff et al. 2008). However, little is known about the rates of substance use problems or substance use disorder (SUD) in this group. A recent literature review found that clinical assessment of substance use among individuals with ASD is infrequent, and the overall scientific evidence and understanding of potential relationships...

This is a preview of subscription content, log in to check access.

References and Reading

  1. Abdallah, M. W., Greaves-Lord, K., Grove, J., Nørgaard-Pedersen, B., Hougaard, D. M., & Mortensen, E. L. (2011). Psychiatric comorbidities in autism spectrum disorders: findings from a Danish Historic Birth Cohort. European child & adolescent psychiatry, 20(11-12), 599–601.CrossRefGoogle Scholar
  2. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Publishing.Google Scholar
  3. Arnevik, E. A., & Helverschou, S. B. (2016). Autism spectrum disorder and co-occurring substance use disorder – A systematic review. Substance Abuse: Research and Treatment, 10, SART.S39921.  https://doi.org/10.4137/SART.S39921.Google Scholar
  4. Baio, J., Wiggins, L., Christensen, D. L., Maenner, M. J., Daniels, J., Warren, Z., et al. (2018). Prevalence of autism spectrum disorder among children aged 8 years – Autism and developmental disabilities monitoring network, 11 sites, United States, 2014. MMWR Surveillance Summaries, 67(6), 1.CrossRefGoogle Scholar
  5. Bauman, M. L. (2010). Medical comorbidities in autism: Challenges to diagnosis and treatment. Neurotherapeutics, 7(3), 320–327.  https://doi.org/10.1016/j.nurt.2010.06.001.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Howlin, P. (2005). Outcomes in autism spectrum disorders. In Handbook of autism and pervasive developmental disorders (Vol. 1, pp. 201–220). John Wiley & Sons Inc, 1997 New York.CrossRefGoogle Scholar
  7. Howlin, P., Goode, S., Hutton, J., & Rutter, M. (2004). Adult outcome for children with autism. Journal of Child Psychology and Psychiatry, 45(2), 212–229.CrossRefGoogle Scholar
  8. Joshi, G., Petty, C., Wozniak, J., Henin, A., Fried, R., Galdo, M., et al. (2010). The heavy burden of psychiatric comorbidity in youth with autism spectrum disorders: A large comparative study of a psychiatrically referred population. Journal of Autism and Developmental Disorders, 40(11), 1361–1370.CrossRefGoogle Scholar
  9. Kronenberg, L. M., Slager-Visscher, K., Goossens, P. J., van den Brink, W., & van Achterberg, T. (2014). Everyday life consequences of substance use in adult patients with a substance use disorder (SUD) and co-occurring attention deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD): A patient’s perspective. BMC Psychiatry, 14(1), 194.  https://doi.org/10.1186/s12888-014-0264-1.CrossRefGoogle Scholar
  10. Mattila, M.-L., Hurtig, T., Haapsamo, H., Jussila, K., Kuusikko-Gauffin, S., Kielinen, M., et al. (2010). Comorbid psychiatric disorders associated with Asperger syndrome/high-functioning autism: A community-and clinic-based study. Journal of Autism and Developmental Disorders, 40(9), 1080–1093.CrossRefGoogle Scholar
  11. Muskens, J. B., Velders, F. P., & Staal, W. G. (2017). Medical comorbidities in children and adolescents with autism spectrum disorders and attention deficit hyperactivity disorders: A systematic review. European Child & Adolescent Psychiatry, 26(9), 1093–1103.  https://doi.org/10.1007/s00787-017-1020-0.CrossRefGoogle Scholar
  12. Palmquist, E., Claeson, A.-S., Neely, G., Stenberg, B., & Nordin, S. (2014). Overlap in prevalence between various types of environmental intolerance. International Journal of Hygiene and Environmental Health, 217(4-5), 427–434.  https://doi.org/10.1016/j.ijheh.2013.08.005.CrossRefPubMedGoogle Scholar
  13. Siegel, M., & Beaulieu, A. A. (2011). Psychotropic medications in children with autism spectrum disorders: A systematic review and synthesis for evidence-based practice. Journal of Autism and Developmental Disorders, 42(8), 1592–1605.  https://doi.org/10.1007/s10803-011-1399-2.CrossRefGoogle Scholar
  14. Simonoff, E., Pickles, A., Charman, T., Chandler, S., Loucas, T., & Baird, G. (2008). Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. Journal of the American Academy of Child and Adolescent Psychiatry, 47(8), 921–929.  https://doi.org/10.1097/CHI.0b013e318179964f.CrossRefPubMedGoogle Scholar
  15. Williamson, E. D., & Martin, A. (2010). Psychotropic medications in autism: Practical considerations for parents. Journal of Autism and Developmental Disorders, 42(6), 1249–1255.  https://doi.org/10.1007/s10803-010-1144-2.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of educationUIT – The Arctic University of NorwayTromsøNorway
  2. 2.Child Study CenterYale School of MedicineNew HavenUSA
  3. 3.Faculty of EducationØstfold University CollegeHaldenNorway
  4. 4.Department of PsychiatryYale School of MedicineNew HavenUSA